![Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer](http://mma.prnewswire.com/media/450388/Lilly_Logo.jpg)
Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer
![PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b316b998a6f3d4685942edb98b16960acc9a40c/4-Figure2-1.png)
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar
![Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy | SpringerLink Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12282-021-01239-8/MediaObjects/12282_2021_1239_Fig1_HTML.png)
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy | SpringerLink
![Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram](https://www.researchgate.net/publication/330450344/figure/fig1/AS:718776249110528@1548381020006/Progression-free-survival-a-Investigator-assessed-and-b-Independent-central-review-in.jpg)
Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram
![The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.,JAMA Oncology - X-MOL The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.,JAMA Oncology - X-MOL](https://xpic.x-mol.com/20200110%2F10.1001_jamaoncol.2019.4782.jpg)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.,JAMA Oncology - X-MOL
![A Breast Cancer Roundtable: CDK4/6 Inhibition, HER2-Positive Disease, and the Role of Immunotherapy – OBR A Breast Cancer Roundtable: CDK4/6 Inhibition, HER2-Positive Disease, and the Role of Immunotherapy – OBR](https://d35jxi6u74c0cz.cloudfront.net/uploads/2020/07/01145801/Fig2_Breast_Roundtable-1024x582.jpg)
A Breast Cancer Roundtable: CDK4/6 Inhibition, HER2-Positive Disease, and the Role of Immunotherapy – OBR
![Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors | Cancer Discovery Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors | Cancer Discovery](https://cancerdiscovery.aacrjournals.org/content/candisc/6/7/740/F5.large.jpg)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors | Cancer Discovery
![Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2020/08/Figures-Tables-EL.jpg)
Review of the Latest Developments in Treatment of Hormone Receptor-Positive Advanced Breast Cancer - European Medical Journal
![A Breast Cancer Roundtable: CDK4/6 Inhibition, HER2-Positive Disease, and the Role of Immunotherapy – OBR A Breast Cancer Roundtable: CDK4/6 Inhibition, HER2-Positive Disease, and the Role of Immunotherapy – OBR](https://d35jxi6u74c0cz.cloudfront.net/uploads/2020/07/01150410/Fig1_Breast_Roundtable-1-1024x574.jpg)
A Breast Cancer Roundtable: CDK4/6 Inhibition, HER2-Positive Disease, and the Role of Immunotherapy – OBR
![PDF) MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer PDF) MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer](https://i1.rgstatic.net/publication/339545587_MONARCH_2_Overall_survival_of_abemaciclib_plus_fulvestrant_in_patients_with_HR_HER2-_advanced_breast_cancer/links/5e7fcd94299bf1a91b866e25/largepreview.png)
PDF) MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
![MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-018-0097-z/MediaObjects/41523_2018_97_Fig3_HTML.png)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
![Matteo Lambertini, MD PhD on Twitter: "#ESMO19 Presidential Session abstract 1 - updated results from #MONARCH2: significant improvement in overall survival with the addition of #abemaciclib to #fulvestrant in advanced endocrine resistant Matteo Lambertini, MD PhD on Twitter: "#ESMO19 Presidential Session abstract 1 - updated results from #MONARCH2: significant improvement in overall survival with the addition of #abemaciclib to #fulvestrant in advanced endocrine resistant](https://pbs.twimg.com/media/EFo7oYFWkAAMaTM.jpg)
Matteo Lambertini, MD PhD on Twitter: "#ESMO19 Presidential Session abstract 1 - updated results from #MONARCH2: significant improvement in overall survival with the addition of #abemaciclib to #fulvestrant in advanced endocrine resistant
![Oncoinfo on Twitter: "#MONARCH-2: median OS benefits in overall survival of abemaciclib+fulvestrant in pts with HR+, HER2- advanced BC. @GeorgeSledge51 #ESMO19 #bcsm @barni_sandro @tmprowell @jrgralow @BreastDocUK @kristinrojasmd @ErikaHamilton9 ... Oncoinfo on Twitter: "#MONARCH-2: median OS benefits in overall survival of abemaciclib+fulvestrant in pts with HR+, HER2- advanced BC. @GeorgeSledge51 #ESMO19 #bcsm @barni_sandro @tmprowell @jrgralow @BreastDocUK @kristinrojasmd @ErikaHamilton9 ...](https://pbs.twimg.com/media/EFo7VDiXoAAINKf.jpg)
Oncoinfo on Twitter: "#MONARCH-2: median OS benefits in overall survival of abemaciclib+fulvestrant in pts with HR+, HER2- advanced BC. @GeorgeSledge51 #ESMO19 #bcsm @barni_sandro @tmprowell @jrgralow @BreastDocUK @kristinrojasmd @ErikaHamilton9 ...
![PDF] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar PDF] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/921c4588aa41f40a34f920dd47d9999027830b13/4-Figure2-1.png)
PDF] MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar
![PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b316b998a6f3d4685942edb98b16960acc9a40c/5-Figure4-1.png)
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar
![MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-018-0097-z/MediaObjects/41523_2018_97_Fig1_HTML.png)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer
![PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1b316b998a6f3d4685942edb98b16960acc9a40c/6-Figure5-1.png)